First Patient Enrolled in CAR T Cell Therapy Trial for Multiple Sclerosis
Similar Articles
Modified CAR-T Cell Therapy Shows Promising HIV Suppression in Early Trial
Gleevec, a Cancer Drug Developed Through Clinical Trials, Continues to Save Lives Decades After Approval
Pancreatic Cancer Survival Advances Through New Drugs and Vaccines
Immunotherapy Shows Promise as Pre-Surgery Treatment for Specific Bowel Cancer
Pre-Surgery Immunotherapy Shows Promise for a Subtype of Colorectal Cancer
Jan Janisch-Hanzlik, a 49-year-old former nurse living near Blair, has become the first patient enrolled in a CAR T cell therapy trial at the University of Nebraska Medical Center in Omaha. The trial is investigating the use of the therapy, originally developed for cancer, to treat autoimmune conditions like multiple sclerosis. Hundreds of similar clinical trials are now exploring this approach for various autoimmune diseases.
Facts First
- Jan Janisch-Hanzlik is the first patient in a CAR T cell therapy trial at the University of Nebraska Medical Center.
- The trial is investigating a treatment originally designed for cancer for use against autoimmune conditions like multiple sclerosis.
- Hundreds of clinical trials are now offering CAR T cell therapy for autoimmune diseases including lupus and Graves' disease.
- Janisch-Hanzlik transitioned from nursing to a desk job due to her multiple sclerosis.
What Happened
Jan Janisch-Hanzlik has enrolled as the first patient in a CAR T cell therapy trial at the University of Nebraska Medical Center (UNMC) in Omaha. The therapy was originally designed to reprogram a patient's own immune cells to target and eliminate cancer, but it is now being offered in hundreds of clinical trials for autoimmune conditions, including multiple sclerosis, lupus, Graves' disease, and vasculitis.
Why this Matters to You
If you or someone you know lives with an autoimmune disease like multiple sclerosis or lupus, this trial represents a significant shift in research. The adaptation of a powerful cancer-fighting technology to target autoimmune disorders could potentially lead to new, more effective treatment options in the future. This expansion of clinical trials means more patients may have access to novel therapies that aim to address the root cause of their condition, rather than just managing symptoms.
What's Next
The enrollment of the first patient marks the beginning of this specific trial at UNMC. The results from this and hundreds of other similar trials worldwide will determine whether CAR T cell therapy is a safe and effective long-term treatment for autoimmune diseases. Successful outcomes could lead to broader regulatory approval and availability of this therapy for conditions that currently have limited curative options.